ABSTRACT Background: On ingestion of gliadin, the major protein component of wheat and other cereals, the celiac intestine is characterized by the proliferation of crypt enterocytes with an inversion of the differentiation/proliferation program. Gliadins and A-gliadin peptide P31-43, in particular, act as growth factors for crypt enterocytes in patients with celiac disease (CD). The effects of gliadin on crypt enterocyte proliferation and activation of innate immunity are mediated by epidermal growth factors (EGFs) and innate immunity mediators [interleukin 15 (IL15)]. Objective: The aim of this study was to determine the molecular basis of proliferation and innate immune response to gliadin peptides in enterocytes. Design: The CaCo-2 cell line was used to study EGF-, IL15-, and P31-43-induced proliferation. Silencing messenger RNAs and blocking EGF receptor and IL15 antibodies have been used to study proliferation in CaCo-2 cells and intestinal biopsy samples from patients with CD and control subjects. Results: In the CaCo-2 cell model, IL15 and EGF cooperated to induce proliferation in intestinal epithelial cells at both the transcriptional and posttranscriptional levels, and the respective receptors interacted to activate each other's signaling. In addition, the effects of the P31-43 peptide on CaCo-2 cell proliferation and downstream signaling were mediated by cooperation between EGF and IL15. The increased crypt enterocyte proliferation in intestinal biopsy samples from patients with CD was reduced by EGF receptor and IL15 blocking antibodies only when used in combination. Conclusions: EGF receptor/IL15R-a cooperation regulates intestinal epithelial cell proliferation induced by EGF, IL15, and the gliadin peptide P31-43. Increased proliferation of crypt enterocytes in the intestine of CD patients is mediated by EGF/IL15 cooperation.
INTRODUCTION
Ingested food can cause tissue inflammation through different mechanisms. Nutrient surplus can trigger intracellular stress signals that potentiate proinflammatory signaling (1) . In the intestine and particularly in the enterocytes, nutrients are modulators of various cellular functions and may be involved in tissue immune response and inflammation. Plant-derived dietary compounds, such as indole-3-carbinol, are essential for normal intestinal immune function, specifically the maintenance of intraepithelial lymphocyte homeostasis (2) .
An example of an intestinal inflammatory and remodeling response of the intestine to food is the small intestinal celiac lesion induced by gluten-an alimentary protein present in wheat and other cereals. Celiac disease (CD) 5 is characterized by inflammatory and structural changes resulting in remodeling of the small intestinal mucosa: the celiac intestine is characterized by an inversion of the differentiation and proliferation program of the tissue, with a reduction in the differentiated compartment, up to complete villi atrophy and an increase in the proliferative compartment (3, 4) along with crypt hyperplasia (5) (6) (7) .
These changes are the consequence of sustained mucosal inflammation due to the T helper 1 T-cell response to certain gliadin peptides (eg, the 33-mer A-gliadin peptide) (8) and the innate immune response to other gliadin peptides (eg, A-gliadin peptide P31-43) (9, 10) . Moreover, recent data have shown that gliadin peptides, in particular peptide P31-43, act as growth factors for cell lines such as CaCo-2 and are able to induce proliferation of celiac crypt enterocytes (11) (12) (13) . Because both the 33-mer containing P57-68 (14, 15) and the 25-mer containing P31-43 (P31-55) (16) are very resistant to hydrolysis by gastric, pancreatic, and intestinal proteases, these peptides are active in vivo in the celiac intestine after gluten ingestion.
The innate immune and proliferative response of the celiac intestine to P31-43 is mediated by IL15 and epidermal growth factor (EGF) receptor (EGFR) signaling, because they can be prevented by antibodies that block EGFR or IL15 (11, 13) . In fact, by interfering with endocytic trafficking (12, 17) , gliadin and P31-43 slow down the decay of activated EGFR (11) , resulting in the proliferation of CaCo-2 cells and the crypt enterocytes from intestinal biopsy samples from patients with CD. The proinflammatory cytokine IL15 is also a major mediator of the innate immune response in CD (9, (18) (19) (20) (21) (22) . Therefore, gliadin affects crypt enterocyte proliferation and the activation of innate immunity via growth factors (EGF) and innate immunity mediators (IL15). The molecular basis underlying this cooperation and the role of this cooperation on CD gliadin-mediated mucosal damage remain unknown.
In this study, we used the CaCo-2 cell model to demonstrate that IL15 and EGF cooperate to induce intestinal epithelial cell proliferation, at both the transcriptional and posttranscriptional levels and that the EGF and IL15 receptors interact to mutually activate downstream signaling pathways. Our results show that the effects of P31-43 on CaCo-2 proliferation and activation of downstream signaling are also mediated by cooperation between EGFR and IL15 receptor-a (IL15R-a). Finally, we demonstrated that the increase in crypt enterocyte proliferation in the CD intestine is mediated by EGF/IL15 cooperation.
SUBJECTS AND METHODS

Cell culture, materials, and treatments
CaCo-2 cells were grown for 5 to 6 d in DMEM (Gibco) supplemented with 10% fetal calf serum (Gibco), 100 units penicillin-streptomycin/mL (Gibco), and 1 mmol glutamine/L (Gibco). The medium was changed every 2 d. Lipopolysaccharide-free synthetic peptides (Inbios) (.95% pure, evaluated by matrixassisted laser desorption/ionization time-of-flight mass spectrometry) were obtained by Ultrasart-D20 filtration (Sartorius AG). The amount of lipopolysaccharide in these peptides was below the detection threshold (,0.20 EU/mg), as assessed with the QCL-1000 Kit (Cambrex Corporation). Recombinant human IL15 (R&D Systems) was used at a concentration of 10 ng/mL, and the blocking monoclonal anti-human IL15 antibody (R&D Systems) was used at 5 mg/mL in all experiments. EGF (BD Biosciences) was used at a concentration of 100 ng/mL. Goat anti-human IL15R-a (Santa Cruz Biotechnology), mouse anti-a tubulin (Sigma-Aldrich), and rabbit anti-EGFR (Cell Signaling Celbio) antibodies were used for Western blotting. The P31-43 peptide with the amino acid sequence LGQQQPFPPQQPY was used at a concentration of 100 mg/mL. Bromodeoxyuridine was detected by using an anti-bromodeoxyuridine monoclonal antibody (GE Healthcare) and anti-mouse-Tex-red-conjugated secondary antibody (Molecular Probes). Nuclei were stained with Hoechst (Sigma-Aldrich). The extracellular signal-regulated kinase (ERK)-specific inhibitor PD98059 was used at 50 mmol/L (Alexis Biochemicals).
Proliferation assay
Bromodeoxyuridine incorporation experiments were performed to evaluate cell proliferation as described elsewhere (11) . Anti-EGFR (528) (Santa Cruz Biotechnology) and anti-IL15 (R&D Systems) antibodies were used at concentrations of 2 and 5 mg/mL, respectively. The anti-EGFR 528 antibody recognized the extracellular ligand-binding domain of EGFR and prevented EGFR activation by acting as a ligand competitor (11) . The anti-IL15 antibodies prevented ligand binding to the receptor by binding to the ligand itself (13, 22) .
Samples were incubated with bromodeoxyuridine (100 mmol/L; Sigma-Aldrich) for 3 h before fixing. After paraformaldehyde fixation and triton permeabilization, the cells were stained for bromodeoxyuridine as previously described (11) and were then observed under a microscope (Axiophot microscope; Carl Zeiss MicroImaging Inc).
Silencing experiments
Transfection of silencing IL15R-a (siIL15R-a) was carried out with HIPerFect Transfection Reagent (QIAGEN Italy) according to the manufacturer's instructions. Briefly, 2.5-6 mg IL15R-a siRNA was diluted in 100 mL culture medium without serum to obtain a final siRNA concentration of 50 nmol/L. Twenty mL of HIPerFect Transfection reagent was added to the siRNA mixture by vortex mixing, and the transfection mix was added dropwise onto the CaCo-2 cells cultured under standard growth conditions and further incubated for 72 h.
Transfection of siEGFR was carried out with Lipofectamine RNAiMAX reagent (Invitrogen Milan) according to the manufacturer's instructions. One day before transfection, the cells were plated in growth medium without antibiotics. Subsequent steps were similar to the protocol used for siIL15R-a transfection. Control nonspecific siRNA provided in the silencing kit (Invitrogen) was transfected by using the same conditions. All cells were subsequently processed for Western blot analysis.
The mean (6SD) transfection efficiency was 60% 6 16.36% as evaluated by counting under the fluorescence microscope (Axiophot microscope; Carl Zeiss MicroImaging Inc) as the enhanced green fluorescent protein-expressing (Invitrogen) cells with respect to the total cells highlighted by Hoechst staining.
Immunoprecipitation
Lysates were prepared as described previously (11-13, 23, 24) , and the protein concentration was measured by using a Bio-Rad protein assay kit. Equal amounts of cell lysates (2 mg protein/mL) were used for immunoprecipitation (Cold Spring Harb Protoc Immunoprecipitation 2009 72.1-73.12). IL15R-a was immunoprecipitated by using 2 mg anti-IL15R-a goat polyclonal antibody (Santa Cruz Biotechnology), EGFR was immunoprecipitated by using the IP-specific anti-EGFR mouse monoclonal antibody (mAb, 1:100; Cell Signaling Euroclone), and the control immunoprecipitation reaction was performed as before (11) with an IgG isotype control antibody (Dako) by using the same conditions used for the specific antibodies. Immunoprecipitated proteins were run on an SDS-PAGE denaturing gel and immunoblotted with specific antibodies as described below.
Western blot
Briefly, CaCo-2 cells were starved overnight in DMEM containing 0.1% fetal bovine serum and then stimulated with P31-43, IL15, and EGF at 378C for various time periods. Cells were washed twice and suspended in lysis buffer. Cell lysates or the immunoprecipitates described above were analyzed by SDS-PAGE by using running buffer (Trizma, 25 mmol/L; Glycine, 192 mmol/L; SDS, 0.1%) and transferred onto nitrocellulose membranes (Whatman Gmbh) by using transfer buffer (Trizma, 25 mmol/L; glycine, 192 mmol/L; SDS, 0.1%; methanol, 20%; Sigma-Aldrich). The membranes were then blocked with 5% nonfat dry milk solution and probed with anti-IL15R-a, antityrosine phosphorylated ERK (anti-pY-ERK1/2), and pY-signal transducer and activator of transcription 5 (pY-STAT5) in blotting buffer (3% milk in TTBS; Tris-HCl, pH 8, 20 mmol/L; NaCl, 150 mmol/L; Triton 0.1%).
The blot was stripped by using stripping buffer (Tris-HCl, pH 6.8, 62.5 mmol/L; SDS, 0.1%; 2-mercaptoethanol, 100 mmol/L) at 608C for 15 to 20 min and stained with anti-tubulin, anti-EGFR, anti-ERK1/2, anti-STAT5, and anti-pY as indicated in the figures. All reagents described were purchased from SigmaAldrich, except for SDS, milk, 2-mercaptoethanol, and Triton, which were purchased from BioRad. Bands were visualized with ECL (GE Healthcare) by using exposure times of 2 to 10 min. Band intensity was evaluated by integrating all of the pixels of the band without the background to calculate the average of the pixels surrounding the band (11) .
Polymerase chain reaction analysis
Complementary DNAs were generated from total RNA by using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) (25) . The resulting cDNA samples were subjected to 10 cycles of polymerase chain reaction (PCR) amplification followed by real-time PCR using the TaqMan PreAmp Master Mix Kit Protocol (PN 4366127; Applied Biosystems). Each TaqMan gene expression assay consisted of 2 sequence-specific PCR primers and a fluorescein-amidite-labeled minor-groove-binding probe by TaqMan. Eighty nanograms of total cDNA (as total input RNA) was used for each replicate assay, and 3 replicates were run for each sample in a 96-well plate format. b 2 -Microglobulin was used as the endogenous control gene. Assays were run with 23 Universal PCR Master Mix without uracil-N-glycosylase on a 7300 Real-Time PCR System (Applied Biosystems) using universal cycling conditions (10 min at 958C; 15 s at 958C, 1 min 608C for 40 cycles).
Organ culture studies
For organ culture studies, duodenal biopsy samples were obtained from 10 untreated patients with active CD and 4 subjects affected by gastroesophageal reflux that served as control subjects. The protocol for this study was approved by the Ethical Committee of the University "Federico II," Naples, Italy (ethical approval: C.E. n. 230/05). Written informed consent was obtained from all patients. The biopsy fragments were cultured as reported elsewhere (11, 13) .
Statistical analyses
GraphPad Prism 5.lnk (GraphPad Software) was used for statistical analysis and graphic representation. Statistical analysis of differences was performed by using Student's t test. P , 0.05 was considered statistically significant. One-factor ANOVA, Bonferroni corrected (P , 0.05 was considered statistically significant) was used to analyze the complex in the latter figures.
RESULTS
Effects of EGF, IL15, and P31-43 on CaCo-2 cell proliferation depended on an interplay between IL15R-a and EGFR Both EGF and IL15 induced proliferation of CaCo-2 cells (13), as shown in Figure 1 , A and B. In fact, the percentage of cells that incorporated bromodeoxyuridine increased from 27.7 6 7.2% in the untreated sample to 55.4 6 11.2% and 47.4 6 9.9% in the samples treated with EGF ( Figure 1A ) and IL15 ( Figure  1B ), respectively. As expected, the EGF-induced increase in proliferation was prevented by treatment with anti-EGFR antibody ( Figure 1A ; 23.8 6 22%) and siRNA against EGFR ( Figure 1A ; 29.8 6 9.8%). Similarly, the IL15-induced increase in proliferation was prevented by anti-IL15 antibodies ( Figure 1B Next, we investigated whether EGF and IL15 cooperated to induce cell proliferation. To address this question, we blocked EGF signaling using EGFR-specific antibodies and siRNA to block EGFR while inducing proliferation with IL15. As shown in Figure 1B , both treatments prevented the ability of IL15 to induce cell proliferation. In fact, bromodeoxyuridine incorporation was 22.3 6 2% in the samples treated with IL15 + anti-EGFR and 28.6 6 5.8% in the samples treated with IL15 + siEGFR. Similarly, IL15-blocking antibodies ( Figure 1A ; 29.5 6 7.2%) and siIL15R-a ( Figure 1A ; 24.6 6 7.5) prevented EGF-induced proliferation. These data indicate that there was a functional interplay between the EGF-and IL15-signaling pathways that induced cell proliferation in intestinal epithelial cells.
We previously showed that the P31-43-induced proliferation in CaCo-2 cells was dependent on EGFR and IL15 activation, because the increase was prevented by anti-EGFR and anti-IL15 antibodies (13) . Here, using siRNA knockdown of EGFR and IL15R-a we confirmed that P31-43-induced proliferation depends on the activity of both receptors. The percentage of cells that incorporate bromodeoxyuridine increased from 21 6 8.1% ( Figure 1C ) and 32. 6 4.6% ( Figure 1D ) in the untreated sample to 49.7 6 10.9% and 54.4 6 6.1%, respectively, in the sample treated with P31-43. This increase was prevented by siRNA knockdown of EGFR and IL15R-a (24.7 6 9.4% and 26.6% 6 5.6%, respectively).
Molecular details of EGF and IL15 interplay
To understand the molecular basis of how the cooperation between EGF and IL15 induced CaCo-2 cell proliferation, we determined whether EGFR and IL15R-a could form a complex. As shown in Figure 2 , immunoprecipitation of IL15R-a showed the presence of an IL15R-a/EGFR complex in the untreated sample.
Furthermore, after treatment with IL15 for either 30 min or 3 h, more EGFR was found in complex with IL15R-a and was immunoprecipitated with anti-IL15R-a compared with the untreated sample ( Figure 2 , A and B; 14-and 8.5-fold increase, respectively), and this level decreased after 6 h of treatment EGF/IL15 AND INTESTINAL EPITHELIAL PROLIFERATION IN CD (5.5-fold). We also found that, when in a complex, both receptors were phosphorylated. When tyrosine phosphorylated EGFR (pY-EGFR) and tyrosine phosphorylated IL15R-a (pY-IL15R-a) levels were compared with the immunoprecipitated IL15R-a after treatment with IL15, EGFR phosphorylation was 7-and 6-fold higher ( Figure 2 , A and C) after 30 min and 3 h of treatment, respectively, whereas IL15R-a phosphorylation was 5.3-and 5.8-fold higher ( Figure 2 , A and D), respectively. The phosphorylation of both receptors decreased at 6 h (2.7-and 5.2-fold for EGFR and IL15R-a, respectively). When pY-EGFR was compared with EGFR in the complex, there was a significant increase at 30 min and 3 h after treatment ( Figure 2E ).
We next investigated whether stimulation with EGF could increase IL15R-a/EGFR complex formation. As shown in Figure 3 , more EGFR was found in complex with IL15R-a after a 30-min or 3-h treatment with EGF ( Figure 3 , A and B; 3-and 3.5-fold increase, respectively), and this level decreased after 6 h to only a 2-fold increase compared with untreated cells. In the complex, phosphorylation of both receptors was higher after 30 min and 3 h of treatment compared with the untreated sample. When pY-EGFR and pY-IL15R-a were compared with the immunoprecipitated IL15R-a, we observed that either a 30-min or a 3-h EGF treatment resulted in an increase in EGFR phosphorylation by 4-and 5-fold, respectively ( Figure 3 , A and C) and an increase in IL15R-a phosphorylation by 9.8-and 22-fold, respectively ( Figure 3, A and D) . The phosphorylation of both receptors decreased at 6 h (3.2-and 5.3-fold for EGFR and IL15R-a, respectively). When pY-EGFR was compared with EGFR in the complex, there was an increment of 11 times that was statistically significant ( Figure 3E ; 3 and 6 h).
Taken together, these results suggest that the formation and activation of the EGFR/IL15R-a complex was enhanced by EGF and IL15 in CaCo-2 cells. The EGFR/IL15R-a complex was a multiprotein complex containing several phosphorylated proteins (see Supplemental Figure 1A under "Supplemental data" in the online issue). The isotypic control antibody was not able to immunoprecipitate EGFR or IL15R-a, thereby corroborating the specificity of the relevant antibodies (see Supplemental Figure 1 B and C under "Supplemental data" in the online issue). The EGFR/IL15R-a complex was immunoprecipitated by anti-EGFR antibodies, suggesting that once the complex has been formed, it was immunoprecipitated by antibodies against each component Treatment with anti-IL15 antibodies also reduced EGFinduced complex formation and IL15R-a phosphorylation (Figure 3, A-E) . The isotypic control IgG treatment had no effect on EGF-and IL15-induced complex formation and phosphorylation (Figures 2 and 3, F and G) . These observations were further confirmed by siRNA experiments. We first showed that siIL15R-a and siEGFR reduced IL15R-a (2-fold) and EGFR expression (10-fold), whereas the nonspecific siRNA had no effect on EGFR or IL15R-a levels (see Supplemental Figure  2 under "Supplemental data" in the online issue).
EGFR silencing abolished the phosphorylation of IL15R-a induced by 30 min of treatment with EGF or IL15 and, conversely, siIL15R-a completely abolished EGF-and IL15-induced EGFR phosphorylation (Figure 4, A-D) . The nonspecific siRNA had no effect on EGF-and IL15-induced complex formation and phosphorylation ( Figure 4, E and F) . Therefore, the silencing of EGFR interfered with IL15-mediated activation of IL15R-a, and the silencing of IL15R-a abolished the EGF-mediated activation of EGFR. Taken together, these data indicate that IL15 and EGF induce complex formation and the activation of EGFR and IL15R-a in a reciprocal manner. One-factor ANOVA, Bonferroni corrected: *P , 0.05, **P , 0.01, ***P , 0.01. F: Isotypic control IgG had no effect on the complex formation and phosphorylation induced by IL15. Western blot analysis of immunoprecipitated IL15R-a in CaCo-2 cells treated with isotypic control IgG together with IL15. The upper line was stained for IL15R-a and the second line for EGFR. The third and fourth lines were stained with anti-phosphotyrosine antibodies. Times of treatments are indicated. G: Densitomentric analysis. The relative amounts of EGFR, pY-EGFR, and pY-IL15R-a in the complex were normalized to immunoprecipitated IL15R-a, and the relative amounts of pY-EGFR were normalized to EGFR. Treatments are indicated, and the data represent the means 6 SDs of 3 independent experiments. One-factor ANOVA, Bonferroni corrected: *P , 0.05, **P , 0.01, ***P , 0.01. EGFR, epidermal growth factor receptor; IL15R-a, IL15 receptor-a; pY, tyrosine phosphorylated; UN, untreated.
P31-43 increased EGFR/IL15R-a complex formation and phosphorylation of both receptors
We next examined whether P31-43 could interfere with the EGFR/IL15R-a complex ( Figure 5 ). As shown in Figure 5 
EGF-activated IL15-dependent signaling and vice versa
Next, we investigated the signaling pathways downstream of the EGF and IL15 receptors. The presence of ERK in the complex immunoprecipitated with anti-IL15R-a suggested that the complex was able to recruit other signaling molecules (see Supplemental Figure 1 F and G under "Supplemental data" in the online issue). Both EGF (27) and IL15 (28) were found to activate Densitometric analysis. The relative amounts of EGFR, pY-EGFR, and pY-IL15R-a in the complex in the absence or presence of blocking anti-IL15 antibodies were normalized to immunoprecipitated IL15R-a levels, and the relative amounts of pY-EGFR were normalized to EGFR levels. Times and treatments are indicated. Data represent the means 6 SDs of 3 independent experiments. One-factor ANOVA, Bonferroni corrected: *P , 0.05, **P , 0.01, ***P , 0.01. F: Isotypic control IgG had no effect on the complex formation and phosphorylation induced by EGF. Western blot analysis of immunoprecipitated IL15R-a in CaCo-2 cells treated with isotypic control IgG together with EGF. The upper line was stained for IL15R-a and the second line for EGFR. The third and fourth lines were stained with anti-phosphotyrosine antibodies. Times of treatments are indicated. G: Densitomentric analysis. The relative amounts of EGFR, pY-EGFR. and pY-IL15R-a in the complex were normalized to the immunoprecipitated IL15R-a, and the relative amounts of pY-EGFR were normalized to EGFR. Treatments are indicated, and the data represent the means 6 SDs of 3 independent experiments. One-factor ANOVA, Bonferroni corrected: *P , 0.05, **P , 0.01. EGF, epidermal growth factor; EGFR, EGF receptor; IL15R-a, IL15 receptor-a; pY, tyrosine phosphorylated; UN, untreated.
ERK1/2 within 30 min of treatment ( Figure 7 , A and B; 3-6-fold), and ERK phosphorylation was sustained at 3 and 6 h ( Figure 7 , C-E). Consistent with our expectations, anti-EGFR and anti-IL15R-a antibodies prevented EGF-and IL15-induced ERK phosphorylation (see Supplemental Figure 3 A and B under "Supplemental data" in the online issue). Interestingly, pretreatment with anti-EGFR antibodies reduced the IL15-induced ERK1/2 phosphorylation after 30 min, 3 h, and 6 h ( Figure 7 , C and E). These data indicate that IL15-induced ERK1/2 phosphorylation is largely dependent on EGFR activity.
Reciprocally, EGF-induced ERK1/2 activation was found to be dependent on IL15 activity, because pretreatment with anti-IL15 antibodies reduced ERK1/2 phosphorylation after 3 and 6 h of EGF treatment (Figure 7, D and E) . Similar results were obtained for STAT5-a signaling molecule that was activated by both EGF and IL15 (see Supplemental Figure 3 C-F under "Supplemental data" in the online issue) (27, 28) .
Silencing experiments further confirmed the interplay between EGFR and IL15R-a. As shown in Figure 7 (F and G), siIL15R-a prevented the IL15-and EGF-induced increase of pY-ERK1/2 and siEGFR prevented EGF-and IL15-induced ERK1/2 phosphorylation ( Figure 7, H and I) . Nonspecific siRNAs did not have an effect on EGF-and IL15-induced ERK1/2 phosphorylation ( Figure 7 , L and M). As expected, the ERK-specific inhibitor PD98059 inhibited EGF, and IL15 induced proliferation of CaCo-2 cells ( Figure 7N ).
These data indicate that signaling by the dual-receptor complex was activated by both ligands and that each ligand could Nonspecific siRNA had no effect on complex formation and phosphorylation induced by EGF or IL15. The upper line was stained for IL15R-a and the second line for EGFR. The third and fourth lines were stained with anti-phosphotyrosine antibodies. F: Densitomentric analysis. The relative amounts of EGFR, pY-EGFR, and pY-IL15R-a in the complex were normalized to the immunoprecipitated IL15R-a, and the relative amounts of pY-EGFR were normalized to EGFR IL15R-a levels in siNStransfected CaCo-2 cells. The data represent the means 6 SDs of 3 independent experiments. Student's t test: *P , 0.05, **P , 0.01. G. Western blot analysis of immunoprecipitated IL15R-a in nontransfected CaCo-2 cells untreated or stimulated with EGF or IL15 for 30 min. The upper line was stained for IL15R-a and the second line for EGFR. The third and fourth lines were stained with anti-phosphotyrosine antibodies. Data are representative of 3 independent experiments. H: Densitomentric analysis. The relative amounts of EGFR, pY-EGFR, and pY-IL15R-a in the complex were normalized to the immunoprecipitated IL15R-a, and the relative amounts of pY-EGFR were normalized to EGFR levels in nontransfected cells. Treatments are as indicated, and the data represent the means 6 SDs of 3 independent experiments. Student's t test: *P , 0.05, **P , 0.01. EGF, epidermal growth factor; EGFR, EGF receptor; IL15R-a, IL15 receptor-a; pY, tyrosine phosphorylated; si, silencing; siNS, nonspecific siRNA; UN, untreated. stimulate the other receptor. This finding implied that signaling was activated by the receptor without being stimulated by its own ligand directly.
The cooperation between EGF and IL15 was also effective at the transcriptional level. EGF and IL15 mRNA expression increased after stimulation with IL15 and EGF, respectively. A time course study using quantitative PCR showed a statistically significant increase in EGF mRNA expression after overnight treatment of CaCo-2 cells with EGF or IL15 (see Supplemental Figure 4A under "Supplemental data" in the online issue) and an increase in IL15 mRNA after overnight treatment of CaCo-2 cells with IL15 or EGF (see Supplemental Figure 4B under "Supplemental data" in the online issue). EGF mRNA expression was induced by EGF and IL15 by 6-and 4.3-fold, respectively, and IL15 mRNA expression was induced by IL15 and EGF by 3.6-and 10-fold, respectively. These data indicate that EGF and IL15 can induce their own transcription and their mutual transcription after overnight treatment.
Effects of P31-43 on signaling and transcriptional regulation of EGF and IL15
Next, we evaluated the role of the complex in P31-43-induced signaling to ERK1/2 using siRNA against EGFR or IL15R-a (Figure 8) . P31-43 activated ERK within 30 min of treatment ( Figure 8, A and B; 3.5-fold increment compared with untreated control). Nonspecific siRNA had no effect on P31-43-induced ERK1/2 phosphorylation (Figure 8, C and D) . As shown in Figures 8, E -H, siEGFR and siIL15R-a inhibited the P31-43-induced increase in pY-ERK1/2. As shown in Figure 8I , P31-43-induced proliferation of CaCo-2 cells was found to be dependent on ERK activation. In fact, the ERK-specific inhibitor PD98059 inhibited P31-43-induced proliferation of CaCo-2 cells. P31-43 also activated STAT5, another signaling molecule downstream of the EGFR and IL15R-a pathways (see Supplemental Figure 3 G and H under "Supplemental data" in the online issue) and induced STAT5 phosphorylation within 30 min after treatment.
Pretreatment with anti-EGFR and anti-IL15 antibodies prevented P31-43-induced STAT5 phosphorylation. Taken together, these data indicate that P31-43 enhanced complex formation and signaling downstream of EGFR and IL15R-a.
A time course experiment showed that P31-43 stimulation of CaCo-2 cells induced an autocrine loop, which resulted in a statistically significant increase in IL15 and EGF mRNA levels only after overnight treatment (Figure 8 , L and M; 2.8-and 2.7-fold, respectively). These data indicate that P31-43 induced the transcription of IL15 and EGF at later time points.
Increased crypt enterocyte proliferation in CD depended on EGF/IL15 interplay Increased proliferation of crypt enterocytes in patients with CD was previously described by several groups (5) (6) (7) 11) . To test the activity of the EGF/IL15 complex on crypt enterocyte proliferation in patients with CD, we obtained biopsy samples from control subjects and patients with CD in the active phase of the disease and cultured them with and without blocking antibodies in the presence of bromodeoxyuridine. As expected, we observed higher proliferation of crypt enterocytes in biopsy samples2 from patients with CD than in samples from control subjects cultured overnight in medium alone (Figure 9 ; 8.4 6 3.9% in control samples and 16.8 6 4.6% in CD samples). The treatment of control biopsy samples with EGFR-and IL15-specific blocking antibodies had no effect, either alone or in combination.
In contrast, the treatment of CD biopsy samples with both blocking antibodies in combination reduced the proliferation of crypt enterocytes to levels similar to those in control subjects (10.8 6 3.3%). Treatment with anti-EGFR alone did not reduce epithelial cell proliferation; however, interestingly, treatment with anti-IL15 antibodies increased the proliferation of enterocytes from patients with CD when compared with untreated enterocytes from patients with CD. The isotypic control antibody did not affect bromodeoxyuridine incorporation in crypt enterocytes of biopsy samples from patients with CD (26) . Taken together, these data indicate that proliferation of crypt enterocytes in the CD environment depends on EGF/IL15 cooperation, and this proliferation of CD enterocytes was blocked only by the inactivation of both receptors. 
EGF/IL15 AND INTESTINAL EPITHELIAL PROLIFERATION IN CD
DISCUSSION
In this study we showed that EGFR/IL15R-a cooperation is crucial for gliadin-induced crypt enterocyte proliferation and activation of the innate immune response in CD. Previous reports from our laboratory and others have indicated that EGF and IL15 induce enterocyte proliferation and that both EGFR and IL15 activity contribute to the gliadin-induced epithelial cell proliferation in CD biopsy samples (11, 13, 29, 30) . In this study, we used CaCo-2 cells, a colon carcinoma-derived intestinal epithelial cell line and a well-known responder to gliadin and gliadin peptides (11, 31) -to demonstrate that IL15 and EGF cooperate to induce enterocyte proliferation. Using specific antibodies and siRNAs, we have shown that blocking EGFR or IL15 signaling prevents IL15-and EGF-dependent cell proliferation. This cooperation is mediated by the formation of a complex between IL15R-a and EGFR, which is increased and activated by each ligand. Signaling, initiating from the complex of the 2 receptors, can be activated by EGF and IL15-each of which is able to stimulate its own cognate receptor and other receptors. Moreover, both EGF and IL15 can induce each other's transcriptional activation.
Complexes of different receptors can amplify the activity of ligands, thereby leading to an extension of downstream signaling. It has been well established in other systems that tyrosine kinase receptors and interleukin receptors are found in cooperating complexes that allow overlapping activities between growth factors and cytokines (32, 33) .
In this article, we provided another example of receptor cooperation that plays a role in the regulation of enterocyte proliferation. The proinflammatory cytokine IL15 is a major mediator of the innate immune response. IL15 plays a nodal role in the immune response in CD by breaking the oral tolerance to gliadin Student's t test: **P , 0.01, ***P , 0.001. BrdU, bromodeoxyuridine; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; IL15R-a, IL15 receptor a; PD, PD98059; pY, tyrosine phosphorylated; si, silencing; siNS, nonspecific siRNA; UN, untreated. (34) . Here, we showed that EGF in CaCo-2 cells is able to regulate the IL15-activated innate immune response pathway through IL15R-a-dependent activation of STAT5 and ERK1/2. Moreover, EGF increases IL15 mRNA in CaCo-2 cells. Interestingly, after EGF, IL15, and P31-43 treatment, ERK1/2 and STAT5 phosphorylation increased within as early as 30 min, whereas the increase in EGF and IL15 mRNA occurred only later (after overnight treatment). This result suggests that the activation of signaling at early time points is independent of the autocrine loop, which occurs at later time points. Therefore, there is an interplay between EGF and IL15 at different levels, from the receptor to downstream signaling at early time points and to mRNA levels at later time points, clearly indicating a role for EGF in the IL15-triggered innate immune pathway in intestinal epithelial cells.
A role for EGF in the innate immune response was previously described in other systems (35, 36) , and previous reports suggest that airway epithelial surface signaling through EGFR is a convergent pathway resulting in innate immune responses to a variety of infectious and noninfectious noxious stimuli (37) . In the skin, EGFR and IL-1 signaling synergistically promote keratinocyte antimicrobial defenses in a differentiation-dependent manner (38) .
In CD, some gliadin peptides (eg, P31-43) induce intestinal damage, which is largely characterized by the IL15-mediated innate immune response and proliferation of crypt enterocytes. The gliadin peptide P31-43 increases crypt enterocyte proliferation in patients with CD in an EGF/IL15-dependent manner and increases IL15 activity in the celiac intestine by interfering with endocytic trafficking (11, 12) . In this article, we showed that P31-43-induced CaCo-2 cell proliferation depends on EGFR/ IL15R-a cooperation. We showed that P31-43-induced proliferation in CaCo-2 cells can be prevented by treatment with anti-EGF and anti-IL15 blocking antibodies and by silencing EGFR and IL15R-a. P31-43 augments dual-receptor complex Experiments were performed in triplicate, and the data from 3 independent experiments were averaged. Columns represent the means 6 SDs. Student's t test: *P , 0.05. BrdU, bromodeoxyuridine; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; IL15R-a, IL15 receptor-a; mRNA, messenger RNA; ON, overnight; PCR, polymerase chain reaction; pY, tyrosine phosphorylated; RQ, relative quantity of mRNAs; si, silencing; siNS, nonspecific siRNA; UN, untreated.
formation and receptor phosphorylation, resulting in increased downstream signaling. Moreover, P31-43 also increases IL15 and EGF mRNA levels in CaCo-2 cells. These effects of P31-43 on CaCo-2 cells suggest a molecular mechanism for gliadin-induced enterocyte proliferation and activation of innate immunity in the celiac intestine. Moreover, our results highlight a novel role for undigested alimentary peptides in the induction and maintenance of enterocyte signaling and proliferation.
This cooperation between IL15R-a and EGFR was also found to regulate the increase in enterocyte proliferation in CD mucosa. Here, we showed that the increase in crypt enterocyte proliferation in CD mucosa specifically depends on the EGF/IL15 interplay. Increased enterocyte proliferation in intestinal biopsy samples from patients with CD in the active phase of the disease was prevented by the combined use of anti-EGFR and anti-IL15 antibodies. Interestingly, anti-IL15 antibodies increased the proliferation of crypt enterocytes in CD mucosa, but anti-EGFR antibodies did not, which indicated that a tightly regulated interplay between EGF and IL15 is involved in the regulation of CD crypt enterocyte proliferation. Although IL15 and EGF can induce proliferation of intestinal crypts in several different situations (39), they do not seem to be involved in basal crypt proliferation (40) , which suggests that EGFR/IL15R-a cooperation is mainly involved in the response to pathological situations.
In conclusion, these data show that an undigested gliadin peptide is a modulator of various cellular functions and may be involved in tissue inflammation and remodeling via its effects on the cooperation between growth factors and cytokines.
